Stephens lowered the firm’s price target on Certara (CERT) to $12 from $15 and keeps an Overweight rating on the shares after the company appointed Jon Resnick as CEO and member of the board, succeeding William Feehery, and reaffirmed its FY25 outlook with the announcement. The firm, which believes this leadership change should be viewed as a potential catalyst on commercial execution, “rather than a precursor of deeper change or strategy shift,” cites its post-Q3 model updates for its revised price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara’s Strategic Transition: Balancing Growth Prospects with Short-term Uncertainties
- Certara Appoints Jon Resnick as New CEO
- Certara appoints Jon Resnick as CEO, William Feehery to step down December 31
- FDA guides on streamlined nonclinical monoclonal antibody safety studies
- Certara initiated with a Buy at Rothschild & Co Redburn